See the factory by live video walkthrough
Book an on-site factory visit in Guangzhou
Marketing a lash serum as “longer,” “thicker,” or “fuller” may sound like standard cosmetic language—but in the U.S., these words can trigger an automatic reclassification from a cosmetic to a drug. Brands that cross…
Marketing a lash serum as “longer,” “thicker,” or “fuller” may sound like standard cosmetic language—but in the U.S., these words can trigger an automatic reclassification from a cosmetic to a drug. Brands that cross that line without proper filings face FDA warning letters, product seizures, and a permanent loss of retailer trust. Understanding exactly where cosmetic claims stop and drug claims begin is not just a labeling nuance; it’s a foundation decision that shapes your formulation, testing, and launch timeline.
Under the Federal Food, Drug, and Cosmetic Act, a product’s intended use determines its regulatory status. A cosmetic is “intended to be applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.” A drug is “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” or “intended to affect the structure or any function of the body.” Lash products fall into a tight regulatory space where wording alone can shift the product into the drug category.
The FDA distinguishes between claims that describe surface-level, temporary improvement and those that imply a change in the body’s structure or function. Phrases like “promotes growth,” “extends the anagen phase,” or “stimulates follicles” directly assert a physiological effect. These are drug claims. Even softer language such as “makes lashes stronger” or “reduces lash fall” can be interpreted as structural-function statements, which the FDA typically treats as disease prevention or treatment claims.
In contrast, purely cosmetic claims focus on how the product makes the lashes look right now: “conditions lashes,” “adds a glossy finish,” “helps lashes appear thicker.” The word “appear” is often the critical safety valve—it signals an optical or temporary cosmetic effect rather than a biological change.
Many of the most common terms used to sell lash serums sit directly on the boundary. The table below shows how the FDA may interpret them.
| Common Marketing Term | Likely FDA Classification | Why It’s Risky |
|---|---|---|
| “Stimulates lash growth” | Drug | Declares a biological action; requires a New Drug Application (NDA) or OTC monograph compliance. |
| “Lengthens lashes” (implied permanent) | Likely drug | Without qualifiers, suggests a physiological change over time. |
| “Fuller-looking lashes” | Cosmetic | With the “looking” modifier, limits to immediate appearance. |
| “Reduces breakage” | May be considered drug | Implies strengthening below the surface; the line depends on context. |
| “Conditions and adds luster” | Cosmetic | Describes surface properties without a structural claim. |
Context matters enormously. A single “stimulates” on a product page can trigger a review even if the rest of the label reads as a cosmetic. Similarly, before-and-after imagery paired with implied persistence often becomes the basis for enforcement.
When a lash product is marketed with drug claims but has not been approved as a drug, the FDA considers it an unapproved new drug. The agency can issue a Warning Letter, mandate a product recall, or detain shipments at the border. For brands sold through major U.S. retailers, a warning letter frequently results in immediate delisting. Even after corrective action, the compliance history remains visible in FDA enforcement databases.
Beyond regulatory consequences, a misclassified product carries elevated liability risk. Competitor challenges, consumer class actions, and challenges from state attorneys general often cite FDA violation history as evidence of deceptive marketing.
Staying firmly in the cosmetic lane does not mean abandoning persuasive copy. It means choosing adjectives and outcome claims that are sensory, sensory-adjacent, or appearance-focused. These principles help:
A strong filing cabinet protects a brand long before a regulator asks questions. For lash products, manufacturers and brand owners should maintain:
Using “growth serum” as a product name is extremely risky. The FDA often views the name itself as an intended-use statement. “Lash conditioning serum” or “lash enhancing cosmetic” is usually safer, provided ingredient descriptions remain strictly cosmetic.
Prostaglandin analogs (e.g., isopropyl cloprostenate) have come under FDA scrutiny precisely because they can affect lash growth by a pharmacological mechanism. Using such an ingredient and then claiming “cosmetic” status may be viewed as misbranding. If a formula relies on a prostaglandin analog, it should be reviewed as a potential drug candidate with appropriate regulatory approvals before marketing.
No. There is no cosmetic label pre-approval process. However, the FDA can act at any time if it deems claims to be drug-like. The burden of self-classification rests entirely with the manufacturer and distributor.
Cosmetic claim substantiation typically relies on consumer perception studies (e.g., “80% of panelists agreed lashes looked fuller after 4 weeks”) or instrumental tests showing an immediate change in appearance. The key is that the study design measures a visible, surface-level effect, not a biological change.
Yes—if they illustrate a cosmetic, temporary effect and are accompanied by careful language. Avoid implying a change in the body’s structure or function. The images should be supported by claim substantiation data and the context should not promise continued improvement beyond the period of use.
The difference between a smooth U.S. launch and an FDA enforcement action often comes down to a handful of words on the front panel. By choosing appearance-based language, avoiding structural function claims, and keeping a complete claim support file, brands can confidently market lash products without sliding into the drug category. The key is to treat claims review not as a last-minute legal check but as a core part of formulation and package design from day one.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.
